{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T16:32:50Z","timestamp":1762101170228},"reference-count":33,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2011,8,1]],"date-time":"2011-08-01T00:00:00Z","timestamp":1312156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pulmonary Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2011,8]]},"DOI":"10.1016\/j.pupt.2011.03.003","type":"journal-article","created":{"date-parts":[[2011,3,16]],"date-time":"2011-03-16T08:49:04Z","timestamp":1300265344000},"page":"386-393","source":"Crossref","is-referenced-by-count":16,"title":["Urantide alleviates monocrotaline induced pulmonary arterial hypertension in Wistar rats"],"prefix":"10.1016","volume":"24","author":[{"given":"Yifang","family":"Mei","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Tian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Han","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanping","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiyi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fanchao","family":"Meng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pupt.2011.03.003_bib1","doi-asserted-by":"crossref","first-page":"343","DOI":"10.7326\/0003-4819-115-5-343","article-title":"Survival in patients with primary pulmonary hypertension. Results from a national prospective registry","volume":"115","author":"D\u2019Alonzo","year":"1991","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.pupt.2011.03.003_bib2","doi-asserted-by":"crossref","first-page":"40S","DOI":"10.1016\/j.jacc.2004.02.032","article-title":"Diagnosis and differential assessment of pulmonary arterial hypertension","volume":"43","author":"Barst","year":"2004","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.pupt.2011.03.003_bib3","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJM199701093360207","article-title":"Primary pulmonary hypertension","volume":"336","author":"Rubin","year":"1997","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pupt.2011.03.003_bib4","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/332411a0","article-title":"A\u00a0novel potent vasoconstrictor peptide produced by vascular endothelial cells","volume":"332","author":"Yanagisawa","year":"1988","journal-title":"Nature"},{"key":"10.1016\/j.pupt.2011.03.003_bib5","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1586\/erc.09.148","article-title":"Bosentan for chronic thromboembolic pulmonary hypertension","volume":"7","author":"Confalonieri","year":"2009","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"10.1016\/j.pupt.2011.03.003_bib6","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.resp.2009.11.005","article-title":"Improvement of bleomycin-induced pulmonary hypertension and pulmonary fibrosis by the endothelin receptor antagonist bosentan","volume":"170","author":"Schroll","year":"2010","journal-title":"Respir Physiol Neurobiol"},{"key":"10.1016\/j.pupt.2011.03.003_bib7","doi-asserted-by":"crossref","first-page":"607","DOI":"10.2147\/VHRM.S4713","article-title":"Bosentan in the treatment of pulmonary arterial hypertension with the focus on the mildly symptomatic patient","volume":"5","author":"Valerio","year":"2009","journal-title":"Vasc Health Risk Manag"},{"key":"10.1016\/j.pupt.2011.03.003_bib8","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/45809","article-title":"Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14","volume":"401","author":"Ames","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.pupt.2011.03.003_bib9","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1016\/j.peptides.2004.04.017","article-title":"Urotensin II in the cardiovascular system","volume":"25","author":"Richards","year":"2004","journal-title":"Peptides"},{"key":"10.1016\/j.pupt.2011.03.003_bib10","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/sj.bjp.0704924","article-title":"Is urotensin-II the new endothelin?","volume":"137","author":"Maguire","year":"2002","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pupt.2011.03.003_bib11","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s00210-001-0503-0","article-title":"Effects of human urotensin II in isolated vessels of various species; comparison with other vasoactive agents","volume":"365","author":"Camarda","year":"2002","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.pupt.2011.03.003_bib12","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.peptides.2007.06.025","article-title":"Immunolocalization of urotensin II and its receptor in human adrenal tumors and attached non-neoplastic adrenal tissues","volume":"29","author":"Morimoto","year":"2008","journal-title":"Peptides"},{"key":"10.1016\/j.pupt.2011.03.003_bib13","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/sj.bjp.0704671","article-title":"Molecular and pharmacological characterization of genes encoding urotensin-II peptides and their cognate G-protein-coupled receptors from the mouse and monkey","volume":"136","author":"Elshourbagy","year":"2002","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pupt.2011.03.003_bib14","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/sj.bjp.0703314","article-title":"Contractile responses to human urotensin-II in rat and human pulmonary arteries: effect of endothelial factors and chronic hypoxia in the rat","volume":"130","author":"MacLean","year":"2000","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pupt.2011.03.003_bib15","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1203\/PDR.0b013e3181c345ea","article-title":"Urotensin-II contributes to pulmonary vasoconstriction in a perinatal model of persistent pulmonary hypertension of the newborn secondary to meconium aspiration syndrome","volume":"67","author":"Simpson","year":"2010","journal-title":"Pediatr Res"},{"key":"10.1016\/j.pupt.2011.03.003_bib16","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1161\/01.ATV.0000154279.98244.eb","article-title":"Human urotensin II is a novel activator of NADPH oxidase in human pulmonary artery smooth muscle cells","volume":"25","author":"Djordjevic","year":"2005","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.pupt.2011.03.003_bib17","doi-asserted-by":"crossref","first-page":"H925","DOI":"10.1152\/ajpheart.2001.280.2.H925","article-title":"Potent vasodilator responses to human urotensin-II in human pulmonary and abdominal resistance arteries","volume":"280","author":"Stirrat","year":"2001","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.pupt.2011.03.003_bib18","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1160\/TH07-04-0294","article-title":"Urotensin-II in the lung: a matter for vascular remodelling and pulmonary hypertension?","volume":"98","author":"Djordjevic","year":"2007","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.pupt.2011.03.003_bib19","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S1071-9164(98)80008-0","article-title":"Angiotensin II blockade followed by growth hormone as adjunctive therapy after experimental myocardial infarction","volume":"4","author":"Hongo","year":"1998","journal-title":"J\u00a0Card Fail"},{"key":"10.1016\/j.pupt.2011.03.003_bib20","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s003950070018","article-title":"Effects of growth hormone on cardiac dysfunction and gene expression in genetic murine dilated cardiomyopathy","volume":"95","author":"Hongo","year":"2000","journal-title":"Basic Res Cardiol"},{"key":"10.1016\/j.pupt.2011.03.003_bib21","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1152\/jappl.1997.82.5.1493","article-title":"Role of inhibition of nitric oxide production in monocrotaline-induced pulmonary hypertension","volume":"82","author":"Mathew","year":"1997","journal-title":"J\u00a0Appl Physiol"},{"key":"10.1016\/j.pupt.2011.03.003_bib22","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1038\/76282","article-title":"Complete reversal of fatal pulmonary hypertension in rats by a serine elastase inhibitor","volume":"6","author":"Cowan","year":"2000","journal-title":"Nat Med"},{"key":"10.1016\/j.pupt.2011.03.003_bib23","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.peptides.2007.09.012","article-title":"Urotensin-II and cardiovascular remodeling","volume":"29","author":"Papadopoulos","year":"2008","journal-title":"Peptides"},{"key":"10.1016\/j.pupt.2011.03.003_bib24","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.1021\/jm901294u","article-title":"Urotensin-II receptor modulators as potential drugs","volume":"53","author":"Maryanoff","year":"2010","journal-title":"J\u00a0Med Chem"},{"key":"10.1016\/j.pupt.2011.03.003_bib25","doi-asserted-by":"crossref","first-page":"7432","DOI":"10.1021\/jm900683d","article-title":"Nonpeptide urotensin-II receptor antagonists: a new ligand class based on piperazino-phthalimide and piperazino-isoindolinone subunits","volume":"52","author":"Lawson","year":"2009","journal-title":"J\u00a0Med Chem"},{"key":"10.1016\/j.pupt.2011.03.003_bib26","first-page":"967","article-title":"Bosentan, sildenafil, and their combination in the monocrotaline model of pulmonary hypertension in rats","volume":"231","author":"Clozel","year":"2006","journal-title":"Exp Biol Med (Maywood)"},{"key":"10.1016\/j.pupt.2011.03.003_bib27","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/j.jacc.2009.01.004","volume":"53","author":"McLaughlin","year":"2009","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"6","key":"10.1016\/j.pupt.2011.03.003_bib28","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1291\/hypres.29.375","article-title":"Human urotensin II as a link between hypertension and coronary artery disease","volume":"29","author":"Watanabe","year":"2006","journal-title":"Hypertens Res"},{"key":"10.1016\/j.pupt.2011.03.003_bib29","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.vph.2006.08.006","article-title":"Role of the endothelium in pulmonary arterial hypertension","volume":"45","author":"Haworth","year":"2006","journal-title":"Vascul Pharmacol"},{"issue":"4","key":"10.1016\/j.pupt.2011.03.003_bib30","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1056\/NEJM199507273330403","article-title":"Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension","volume":"333","author":"Giaid","year":"1995","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pupt.2011.03.003_bib31","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ejphar.2004.07.089","article-title":"Urantide mimics urotensin-II induced calcium release in cells expressing recombinant UT receptors","volume":"498","author":"Camarda","year":"2004","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pupt.2011.03.003_bib32","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1161\/01.RES.76.5.922","article-title":"Simultaneous measurements of Ca2+ and nitric oxide in bradykinin-stimulated vascular endothelial cells","volume":"76","author":"Blatter","year":"1995","journal-title":"Circ Res"},{"key":"10.1016\/j.pupt.2011.03.003_bib33","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s00380-005-0876-y","article-title":"Inhalation of nebulized nitroglycerin, a nitric oxide donor, for the treatment of pulmonary hypertension induced by high pulmonary blood flow","volume":"21","author":"Puikuan","year":"2006","journal-title":"Heart Vessels"}],"container-title":["Pulmonary Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553911000381?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553911000381?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,9]],"date-time":"2019-06-09T08:25:42Z","timestamp":1560068742000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1094553911000381"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,8]]}},"alternative-id":["S1094553911000381"],"URL":"https:\/\/doi.org\/10.1016\/j.pupt.2011.03.003","relation":{},"ISSN":["1094-5539"],"issn-type":[{"value":"1094-5539","type":"print"}],"subject":[],"published":{"date-parts":[[2011,8]]}}}